EGFR and lung adenocarcinoma: Patients with mutant EGFR-driven lung adenocarcinoma receiving EGFR tyrosine kinase inhibitor (TKI) therapy had better response rates and progression-free survival (PFS) when compared to those receiving traditional standard chemotherapy [1].